Cover Image
市場調查報告書

Biomay AG:產品平台分析

Biomay AG - Product Pipeline Review - 2015

出版商 Global Markets Direct 商品編碼 224572
出版日期 內容資訊 英文 31 Pages
訂單完成後即時交付
價格
Back to Top
Biomay AG:產品平台分析 Biomay AG - Product Pipeline Review - 2015
出版日期: 2015年04月22日 內容資訊: 英文 31 Pages
簡介

Biomay AG (Biomay)是致力於發現與開發緩解疾病性過敏治療藥的生物科技企業。該公司的開發平台產品有BM32(基於基因重組胜肽·載體技術的新花粉過敏·疫苗)及其他胜肽-載體融合蛋白質,低過敏原疫苗,野生型過敏原,BM10,過敏原 mRNA等。

本報告提供Biomay AG的治療藥開發平台現狀及各開發階段比較分析,提供您藥物標的,作用機制,給藥途徑,各分子類型的治療藥評估,最新的企業新聞和發表,後期階段及中止的計劃等相關資訊。

Biomay AG的基本資料

  • Biomay AG概要
  • 主要資訊
  • 企業資料

Biomay AG:R&D概要

  • 主要的治療範圍

Biomay AG:開發平台評估

  • 各開發階段的開發中產品
  • 單劑產品
  • 轉出授權產品
    • 轉出授權產品/聯合治療模式

Biomay AG:開發中產品概況

  • 臨床實驗階段的開發中產品
    • 第二階段的產品/聯合治療模式
    • 第一階段的產品/聯合治療模式
  • 初期階段產品開發中產品
    • 前臨床階段的產品/聯合治療模式

Biomay AG:藥物簡介

  • BM-32
  • Fish Hypoallergenic Vaccine
  • BM-10
  • BM-31
  • Japanese Cedar Hypoallergenic Vaccine
  • Oligonucleotide for Grass Allergy
  • Ragweed Hypoallergenic Vaccine
  • Subunit Vaccine for Cat Allergy
  • Subunit Vaccine for Mite Allergy
  • Subunit Vaccine for Ragweed Allergy
  • Vaccine for Grass Allergy

Biomay AG:開發平台分析

  • 各給藥途徑
  • 各分子類型

Biomay AG:最近的開發平台趨勢

Biomay AG:暫停中的計劃

Biomay AG:總公司和子公司的所在地

附錄

圖表

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GMDHC06960CDB

Summary

Global Markets Direct's, 'Biomay AG - Product Pipeline Review - 2015', provides an overview of the Biomay AG's pharmaceutical research and development focus.

This report provides comprehensive information on the current therapeutic developmental pipeline of Biomay AG's, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. It also reviews latest updates, and featured news and press releases, along with special features on late-stage and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct's team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

  • The report provides brief overview of Biomay AG including business description, key information and facts, and its locations and subsidiaries
  • The report reviews current pipeline of Biomay AG's human therapeutic division and enlists all their major and minor projects
  • The report features product description and descriptive mechanism of action for key pipeline products along with the product's developmental history and major milestones
  • Special feature on out-licensed and partnered product portfolio
  • The report summarizes all the dormant and discontinued pipeline projects
  • Latest company statement
  • Latest news and deals relating to the Biomay AG's pipeline products

Reasons to buy

  • Evaluate Biomay AG's strategic position with total access to detailed information on its product pipeline
  • Assess the growth potential of Biomay AG in its therapy areas of focus
  • Identify new drug targets and therapeutic classes in the Biomay AG's R&D portfolio and develop key strategic initiatives to reinforce pipeline in those areas
  • Exploit in-licensing opportunities by identifying windows of opportunity to fill portfolio gaps
  • Develop strategic initiatives by understanding the focus areas of Biomay AG and exploit collaboration and partnership opportunities
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Plan mergers and acquisitions effectively by identifying the most promising pipeline of Biomay AG
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Explore the dormant and discontinued projects of Biomay AG and identify potential opportunities in those areas
  • Avoid Intellectual Property Rights related issues

Table of Contents

  • Table of Contents
    • List of Tables
    • List of Figures
  • Biomay AG Snapshot
    • Biomay AG Overview
    • Key Information
    • Key Facts
  • Biomay AG - Research and Development Overview
    • Key Therapeutic Areas
  • Biomay AG - Pipeline Review
    • Pipeline Products by Stage of Development
    • Pipeline Products - Monotherapy
    • Pipeline Products - Out-Licensed Products
      • Out-Licensed Products/Combination Treatment Modalities
  • Biomay AG - Pipeline Products Glance
    • Biomay AG - Clinical Stage Pipeline Products
      • Phase II Products/Combination Treatment Modalities
      • Phase I Products/Combination Treatment Modalities
    • Biomay AG - Early Stage Pipeline Products
      • Preclinical Products/Combination Treatment Modalities
  • Biomay AG - Drug Profiles
    • BM-32
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • fish hypoallergenic vaccine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • grass allergy vaccine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • BM-31
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • BM-34
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • BM-35
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • BM-36
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • Japanese cedar hypoallergenic vaccine
      • Product Description
      • Mechanism of Action
      • R&D Progress
    • ragweed hypoallergenic vaccine
      • Product Description
      • Mechanism of Action
      • R&D Progress
  • Biomay AG - Pipeline Analysis
    • Biomay AG - Pipeline Products by Route of Administration
    • Biomay AG - Pipeline Products by Molecule Type
  • Biomay AG - Recent Pipeline Updates
  • Biomay AG - Dormant Projects
  • Biomay AG - Locations And Subsidiaries
    • Head Office
  • Appendix
    • Methodology
    • Coverage
    • Secondary Research
    • Primary Research
    • Expert Panel Validation
    • Contact Us
    • Disclaimer

List of Tables

  • Biomay AG, Key Information
  • Biomay AG, Key Facts
  • Biomay AG - Pipeline by Indication, 2015
  • Biomay AG - Pipeline by Stage of Development, 2015
  • Biomay AG - Monotherapy Products in Pipeline, 2015
  • Biomay AG - Out-Licensed Products in Pipeline, 2015
  • Biomay AG - Out-Licensed Products/ Combination Treatment Modalities, 2015
  • Biomay AG - Phase II, 2015
  • Biomay AG - Phase I, 2015
  • Biomay AG - Preclinical, 2015
  • Biomay AG - Pipeline by Route of Administration, 2015
  • Biomay AG - Pipeline by Molecule Type, 2015
  • Biomay AG - Recent Pipeline Updates, 2015
  • Biomay AG - Dormant Developmental Projects,2015

List of Figures

  • Biomay AG - Pipeline by Top 10 Indication, 2015
  • Biomay AG - Pipeline by Stage of Development, 2015
  • Biomay AG - Monotherapy Products in Pipeline, 2015
  • Biomay AG - Out-Licensed Products in Pipeline, 2015
  • Biomay AG - Pipeline by Top 10 Molecule Type, 2015
Back to Top